228 results about "Gln - Glutamine" patented technology

The invention relates to an engineering bacterium of high-yield ornamental blue as well as a construction method and application of the engineering bacterium, and belongs to the technical field of natural dye synthesis by a biological method. The engineering bacterium capable of highly producing the ornamental blue, disclosed by the invention, expresses icd, bpsA, glnAY405F and gd hA; acnR, yggB, glsK, aceA and ldh are knocked out from the engineering bacteria. According to the application, yggB and aceA genes are knocked out, site-directed mutagenesis (Y405F) is carried out on a glnA gene, a glsK gene is replaced by a glnAY405F gene, an acnR gene is replaced by an icd gene, an ldh gene is replaced by a gdhA gene, and a bpsA gene is integrated, so that the formation of by-products such as lactate and succinic acid in a blue-viewing synthesis process can be blocked; the flow direction of a passage from citric acid to isocitric acid to alpha-ketoglutaric acid to glutamic acid to glutamine is improved, so that the concentration of glutamine in cells is improved, and the yield of the ornamental blue is improved.

The invention discloses corynebacterium glutamicum for producing N-acetylglucosamine and application of the corynebacterium glutamicum, and belongs to the technical field of synthetic biology. Specifically, the corynebacterium glutamicum overexpresses a GNA1 gene from a brewer's yeast S288C controlled by a tacM promoter, a glmS gene from corynebacterium glutamicum S9114 and a yqab gene from escherichia coli K12 MG1655, and simultaneously has five gene defect types of nagA, nagB, ldhA, msccg and msccg2 in a genome and two gene single base mutation types of odhA and glnA, and the codon of the glnA for coding the 405th amino acid is mutated from TAC to TTC. By blocking excretion of glutamic acid of corynebacterium glutamicum and enhancing conversion of glutamic acid to glutamine, the supply capacity of a precursor of corynebacterium glutamicum is enhanced, and an optimal way for synthesizing N-acetylglucosamine is obtained, so that efficient production of N-acetylglucosamine in corynebacterium glutamicum is realized, and the yield of N-acetylglucosamine in corynebacterium glutamicum is increased. The method has important economic value and social significance.

The invention relates to the technical production field of metabolic engineering and genetic engineering, and particularly provides a uracil production strain as well as a construction method and application thereof. According to the strain, a uridine kinase gene udk is knocked out on an E.coli W3110 genome, and meanwhile, a T7RNA polymerase gene is integrated; the uridine monophosphate kinase gene pyrH is weakened; the method comprises the following steps: overexpressing a carbamyl phosphate synthetase gene carAB, a ribose phosphate pyrophosphate kinase gene prsA, a pyrimidine-5 '-nucleoside enzyme gene ppnN, UMP phosphohydrolase genes umpH and umpG, a ribonucleoside hydrolase 1 gene rihA and a glutamine synthetase gene glnA; an orotic acid nucleoside monophosphate decarboxylase gene pyrF and an orotic acid ribosyltransferase gene pyrE of wild type bacillus subtilis B.subtilis 168 are introduced in a heterologous manner, so that an orotate nucleoside monophosphate decarboxylase gene pyrF and an orotate ribosyltransferase gene pyrE are obtained. The safe, efficient and low-cost production of the uracil is realized.

The invention relates to the technical field of genetic engineering, and discloses a genetically engineered bacterium for producing L-arginine as well as a construction method and application of the genetically engineered bacterium. Escherichia coli is taken as a starting strain, and the following treatment is performed: overexpressing genes gdhA and gdh of glutamate dehydrogenase, promoting generation of glutamic acid, overexpressing and coding arginine transporter gene argO to enhance extracellular transport of arginine, introducing exogenous argJ to replace a linear synthesis pathway in large intestines, improving the utilization rate of acetyl coenzyme A and accelerating the synthesis efficiency of arginine; a glutamine synthetase gene glnA is over-expressed, and glutamine synthesis is enhanced; the pckA is overexpressed to promote ATP synthesis; meanwhile, speA and adiA genes for coding the arginine decarboxylase are deleted, so that further synthesis of putrescine from L-arginine is inhibited, and the L-arginine accumulation capability of the strain is improved. Through the combined action of the treatment, a genetically engineered bacterium with extremely high L-arginine production yield is finally obtained, and the shake flask fermentation yield can reach 13.7 g / L.

The invention discloses a gelator and a preparation method and application thereof, the structural formula of the gelator is # imgabs0 #, R1 is a side chain group connected to an amino acid central carbon atom except an amino group, a carboxyl group and a hydrogen atom; the amino acid is selected from one of glycine, alanine, valine, leucine, isoleucine, methionine, proline, tryptophan, serine, tyrosine, cysteine, phenylalanine, asparagine, glutamine, threonine, aspartic acid, glutamic acid, lysine, arginine, histidine, selenocysteine and pyrrole lysine; the amino acid is selected from one of glycine, alanine, valine, leucine, isoleucine, methionine, proline, tryptophan, serine, tyrosine, cysteine, phenylalanine, asparagine, glutamine, threonine, aspartic acid, glutamic acid, lysine, arginine, histidine, selenocysteine and pyrrole lysine; r2 is alkyl with the carbon atom number of 16 to 19; and R3 is 9-fluorenyl methoxy carbonyl group or t-butyloxycarbonyl group. The gelator has a hydrophobic long alkyl tail chain, can spontaneously gather and assemble into a three-dimensional network structure through hydrogen bonds, pi-pi interaction and hydrophobic force, and fixes an oil phase in an oil solvent or an oil-water mixture in an effective manner to form high-strength gel.

The present invention is concerned with a crystalline pharmaceutically acceptable salt of the glutaminyl cyclase inhibitor Varoglutamstat. Varoglutamstat is chemically designated as (S)-1- (1H-benzo[d]imidazol-5-yl)-5-(4-propoxyphenyl)imidazolidin-2-one and is also known under the code PQ912. The invention further relates to a polymorphic form of the hydrochloride salt of (S)- 1-(1H-benzo[d]imidazol-5-yl)-5-(4-propoxyphenyl)imidazolidin-2-one, to processes for preparing said hydrochloride salt and its polymorphic form, pharmaceutical compositions containing the same, therapeutic uses thereof and methods of treatment employing them.

The invention provides a method for improving fermentation yield of glutamine, which is characterized in that a coding gene aspB of aspartate transaminase in a microorganism with glutamine production capacity is weakened by utilizing a genetic engineering means to obtain a modified microorganism, and the modified microorganism is used for fermentation production of glutamine. The aspB gene of corynebacterium glutamicum is modified, so that the glutamine generation capacity of corynebacterium glutamicum is higher than that of an unmodified strain.

The invention discloses a composite inducer for promoting adhesion and metamorphosis of marine bivalve mollusk larvae and an application method of the composite inducer. The composite inducer for promoting adhesion and metamorphosis of the marine bivalve mollusk larvae comprises glutamine, glutamic acid, potassium chloride, calcium chloride and taurine, and the concentration ratio of the glutamine to the glutamic acid to the potassium chloride to the calcium chloride to the taurine is 1: 1: 2 * 10: 1.7 * 10: 4. According to the application, glutamine, potassium ions, calcium ions, glutamic acid and taurine are matched, the application effect of the glutamine, the potassium ions, the calcium ions, the glutamic acid and the taurine in the aspect of improving the attachment and metamorphosis rate of the shellfish larvae is defined, the technical blank of multi-component cooperative regulation and control of the attachment and metamorphosis of the shellfish at present is filled, a new solution is provided for bivalve shellfish fry production, and the application prospect is wide. The method is of great significance in promoting healthy development of the mariculture industry.

The invention discloses a cytochrome P450BM3 mutant and application of the cytochrome P450BM3 mutant in high-selectivity oxidation of 1, 8-cineole to generate 2-hydroxy-1, 8-cineole, and the mutant is obtained by replacing at least one amino acid in the 171st site, the 87th site, the 307th site and the 437th site of an amino acid sequence shown as SEQ ID No.1; the amino acid sequence is mutated into alanine Ala, the 171st site histidine His mutated into leucine Leu, the 87th site phenylalanine Phe mutated into alanine Ala, the 307th site glutamine Gln mutated into histidine His, and the 437th site leucine Leu mutated into valine Val. According to the present invention, by carrying out mutation on the active site of the cytochrome P450BM3, the P450BM3 mutant capable of highly selectively oxidizing 1, 8-cineole to generate 2-hydroxy-1, 8-cineole is finally obtained;

The invention relates to a composite probiotic postbiotic capable of improving intestinal health and application of the composite probiotic postbiotic, and belongs to the technical field of microorganisms, the composite probiotic postbiotic comprises inactivated thalli and / or metabolites of a probiotic composition; the probiotic composition is prepared from the following components: the lactobacillus casei Zhang, the plant lactobacillus P8 and the bifidobacterium animalis subsp. Lactis V9. The preparation method comprises the following steps: preparing the probiotic composition from the lactobacillus casei Zhang, the plant lactobacillus P8 and the bifidobacterium animalis subsp. Lactis V9; researches show that the content of the metabolite of the complex probiotics, such as L-phenylalanyl-L-glutamic acid, glutamic acid-isoleucine, proline-histidine, L-isoleucine-L-arginine, prolyl glutamine, chrysophanol, crocin, tributyric acid and campsis grandiflora saponin C, is remarkably increased, and the content of the metabolite of the complex probiotics is remarkably increased; therefore, the composite probiotic metagen has the effects of enhancing the intestinal barrier function, regulating cellular immunity and intestinal mucosa immunity, resisting inflammation and resisting oxidation.

The embodiment of the present application discloses an oil-in-water composition containing ceramides, and a preparation method and use thereof, which can reduce the phenomenon of crystallization. The oil-in-water composition containing ceramides includes: ceramides, wherein the ceramides are selected from ceramides or ceramide analogs; oil; an emulsifier including sucrose polystearate and sodium di(laurylamide glutamine) lysine; and water; wherein the content of the ceramides is 0.1-10%; the content of the emulsifier is 0.2-6.3%; the mass ratio of the sucrose polystearate to the sodium di(laurylamide glutamine) lysine is 5-60:1; the oil-in-water composition containing ceramides is formed by emulsifying the ceramides, the emulsifier, the oil and the water.

Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for a mutated human RAS amino acid sequence with a substitution of (i) glycine at position 13 with aspartic acid or (ii) glutamine at position 61 with arginine. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.

The invention relates to the field of stem cell biology, and discloses a culture solution and a method for differentiating human pluripotent stem cells into natural killer cells. The culture solution comprises a DMEM (Dulbecco Modified Eagle Medium), an F12 culture medium, an APEL blood cell culture medium, an induction factor, a chemotactic factor CXCL12, L-ascorbic acid, L-glutamine, beta-mercaptoethanol, sodium selenite, ethanolamine and penicillin-streptomycin. The invention also discloses a more efficient differentiation method for inducing the human induced pluripotent stem cells to differentiate into the NK cells, and the differentiation method provided by the invention can rapidly, efficiently, simply and conveniently induce the pluripotent stem cells to differentiate into the natural killer cells at low cost based on a culture medium with definite components and an optimized cell factor combination.

The present application provides certain phenylpiperidine derivatives and pharmaceutically acceptable salts thereof, which are inhibitors of glutamyl peptide cyclotransferase (QPCT) and glutamyl peptide cyclotransferase-like protein (QPCTL), and are therefore useful in the treatment of diseases that can be treated by inhibition of QPCT / L. Also provided are pharmaceutical compositions containing the same, as well as methods for preparing the compounds.

The present invention concerns a cell line comprising an endogenous dihydroorotate dehydrogenase (DHODH) and glutamine synthetase (GS) genes which are partially or fully inactivated, and its use for producing recombinant proteins.

Disclosed are polypeptides that can be used for bioconjugation. The polypeptides have transglutaminase activity, and they can be used to make biomolecule-compound conjugates, for example to conjugate a compound to a specific lysine or glutamine of an antibody.

The invention relates to the technical field of semen preservative preparation, in particular to a diluent preparation capable of prolonging the normal-temperature survival time of boar semen and a preparation method of the diluent preparation. Glucose, L-glutamine, an antioxidant and polysaccharide components are scientifically proportioned, and an innovative polyethyleneimine-polysaccharide copolymer is combined, so that the normal-temperature survival time of boar semen is prolonged; the dual effects of sperm metabolism regulation and cell membrane protection are realized. The polyethyleneimine-polysaccharide copolymer enhances the biocompatibility and protective ability of the diluent through stable cross-linking of amino and carboxyl, and effectively relieves the problem of sudden change of osmotic pressure and acidity of the traditional preservative. In the formula, antioxidant components, such as reduced glutathione, vitamin E and coenzyme Q10, synergistically reduce oxidative stress and delay sperm senescence. According to the whole formula, proper pH and osmotic pressure are guaranteed, the sperm motility and survival time are remarkably prolonged, the requirement of pig industry for long-term preservation of sperm is met, and the feed additive has remarkable application value and popularization potential.

This invention discloses a cyclic lipopeptide delivery system, comprising a cyclic lipopeptide carrier and nucleic acid; the head of the cyclic lipopeptide carrier is composed of heptapeptides R1R2R2R3R4R2R2 linked together by amide bonds to form a ring, and the hydrophobic tail of the cyclic lipopeptide carrier is composed of a fatty acid with a carbon chain length of 6-44 forming an ester bond with the hydroxyl group on the head amino acid R3, with the following general structural formula: where R1 is a basic amino acid, including one of histidine (His), lysine (Lys), or arginine (Arg); R2 is a hydrophobic amino acid, including one of leucine (Leu), isoleucine (Ile), or valine (Val); R3 is a hydrophilic amino acid, including one of tyrosine (Tyr), serine (Ser), or threonine (Thr); R4 is one of glutamate (Glu) or glutamine (Gln); n is an integer from 5 to 43; the cyclic lipopeptide carrier encapsulates the nucleic acid drug to form cyclic lipopeptide-nucleic acid nanoparticles.

Compounds (I) are provided, where R1 and R2 are H or (C1-C3)-alkyl; X is a linear methylene chain of formula —[CH2]n— with n=0, 1 or 2, or a biradical from a branched saturated (C2-C4)-alkylene chain; and A is either a C-radical from a non-aromatic polycyclic 6- to 15-membered carbocyclic ring system, or a C-radical from a polycyclic 6- to 15-membered heterocyclic ring system having one or two O, S or N; wherein the C-radicals are unsubstituted or substituted. Compounds (I) are simultaneously inhibitors of soluble epoxide hydrolase and inhibitors of glutaminyl cyclase. Besides, they reduce the levels of pro-inflammatory cytokines in LPS stimulated BV2 cells, display low cytotoxicity, and have good BBB permeability. Thus, they are useful as multitarget compounds for the prevention or treatment of Alzheimer's disease.

The present invention belongs to the field of biomedicine technology and discloses an anti-glycation amino acid derivative having a structure of general formula I or an isomer of general formula I: #imgabs0# wherein R 1 is selected from the group consisting of alanine, threonine, proline, asparagine, glutamine, leucine, tryptophan, serine, valine, methionine, tyrosine, histidine, L-aspartic acid-4-tert-butyl ester, L-aspartic acid-1-tert-butyl ester, glycine, isoleucine, phenylalanine, lysine, arginine, cysteine, L-glutamic acid-5-tert-butyl ester, and the residue after condensation of L-glutamic acid-1-tert-butyl ester, R 2 Select one of the following structures: -C 15 H 29 ,‑C 15 H 31 ,‑C 15 H 27 , ‑CHOHC 14 H 27 , ‑CHOHC 14 H 29 The present invention also discloses a synthesis method and application of anti-glycation amino acid derivatives. Such compounds improve the fat solubility of amino acid compounds, which is conducive to penetration into the skin, and show excellent effects in anti-oxidation, anti-glycation, skin barrier repair, tissue healing and the like.

This disclosure concerns wild-type and engineered D-Ala-D-Ala ligases (Ddls) and their use for synthesising mycosporine-like amino acids (MAAs), such as MAAs derived from a mycosporine-glutamine backbone and MAAs with hydrophobic side groups. Also disclosed are compositions and uses of the synthesised MAAs.

Disclosed are azotomycin prodrugs their use in treating diseases, disorders, or conditions associated with excess and / or aberrant glutamine utilization, including cancer.

Modified bacteria that produce glutamine are provided wherein a heterologous polynucleotide of glutamine export protein (rarD) and a modification that increases glutamine synthase glnA activity are included in the genome as compared to the pre-modified bacteria. In addition, methods of producing glutamine using the modified bacteria are also provided.

The application discloses a novel double-carrier expression system for protein expression and a construction method and application thereof. The novel double-carrier expression system for protein expression comprises a first carrier containing a nucleotide sequence for coding a first functional domain of glutamine synthetase and a nucleotide sequence of light chain and heavy chain of a protein to be expressed; and a second carrier containing a nucleotide sequence for coding a second functional domain of glutamine synthetase and a nucleotide sequence of a ScFv sequence of the protein to be expressed, and an amino acid sequence of the glutamine synthetase is composed of the first functional domain and the second functional domain. By using the expression system, the transfection efficiency and screening efficiency are greatly improved, and the expression amount of the target protein is obviously increased.

The invention discloses a multi-copper oxidase mutant sourced from Psychrobacter sp. And capable of efficiently degrading biogenic amine and application of the multi-copper oxidase mutant. According to the multi-copper oxidase mutant, the 183rd site of an amino acid sequence shown in SEQ ID NO.1 is mutated into histidine from phenylalanine, the 221st site of the amino acid sequence shown in SEQ ID NO.1 is mutated into aspartic acid from asparagine, the 261st site of the amino acid sequence shown in SEQ ID NO.1 is mutated into glutamic acid from glutamine, and the 292nd site of the amino acid sequence shown in SEQ ID NO.2 is mutated into arginine from lysine. Compared with wild type multi-copper oxidase, the multi-copper oxidase mutant disclosed by the invention has a good degradation effect on tryptamine, phenylethylamine, putrescine, cadaverine, histamine, tyramine, spermidine and spermine, and the degradation rate on the spermidine and the spermine is increased to 100%, so that the multi-copper oxidase mutant has a good application prospect in food fermentation safety production.

The present invention discloses a cyanase mutant, nucleic acid, recombinant expression vector and their applications, belonging to the field of bioengineering. The cyanase gene derived from Escherichia coli E. coli K-12 substr. MG1655 was subjected to site-directed mutagenesis, so that the encoded amino acid sequence was mutated from glycine G to alanine A at the 37th position, from lysine K to arginine R at the 154th position, and from glutamine Q to histidine H at the 51st position. The specific activity of the cyanase mutant G37A / K154R / Q51H of the present invention against potassium cyanate is 2.4 times that before mutation, and the half-lives at 30 °C and 40 °C are increased by 2.1 times and 2.6 times respectively. The cyanase parent of the present invention cannot catalyze potassium cyanide, while the specific activity of the mutant G37A / K154R / Q51H against potassium cyanide reaches 5.5 U / mg, and the half-lives at 30 °C and 40 °C are 2.5 h and 3.0 h respectively. The cyanase mutant of the present invention can efficiently catalyze the decomposition of the substrates potassium cyanate and potassium cyanide, so as to achieve the purpose of degrading cyanide-containing wastewater, and can be widely applied to industries such as chemical engineering, pharmaceuticals and metallurgy, and has broad application prospects.

The invention discloses a 4-hydroxyphenylacetic acid 3-hydroxylase mutant, a coding gene of the 4-hydroxyphenylacetic acid 3-hydroxylase mutant and application of the 4-hydroxyphenylacetic acid 3-hydroxylase mutant and the coding gene of the 4-hydroxyphenylacetic acid 3-hydroxylase mutant. The 4-hydroxyphenylacetic acid 3-hydroxylase mutant is one of the following: glutamine at the 212th site of an amino acid sequence as shown in SEQ ID NO.1 is mutated into alanine, as shown in SEQ ID NO.3; the glutamic acid at the 216th site of the amino acid sequence as shown in SEQ ID NO.1 is mutated into alanine, as shown in SEQ ID NO.4; after the genetically engineered bacteria (Q212A and E216A) are subjected to shake flask fermentation in an M9Y culture medium containing 100 [mu] g / mL of ampicillin for 24 h, the tanshinol yield reaches 757.18 mg / L, and the tanshinol yield reaches 744.36 mg / L. The genetically engineered bacteria are good in substrate specificity in tanshinol biosynthesis, high in catalytic efficiency, simple in process and environmentally friendly.

The invention discloses a genetically engineered bacterium for synthesizing L-glutamine by taking glucose as a carbon source and application of the genetically engineered bacterium. The genetically engineered bacterium takes escherichia coli as a chassis strain; according to the invention, a citrate synthase gene gltA, an aconitic acid hydratase gene can, an isocitrate dehydrogenase gene icd, a glutamate dehydrogenase gene gdh, a glutamine synthetase gene glnA and ammonium transporter genes amt and amtb can be overexpressed. Compared with the prior art, the invention provides a new strain and a new method for biosynthesizing L-glutamine, and the new strain and the new method have the significances of economy, scientificity, low cost, simple process and large-scale production.

The invention belongs to the technical field of gene therapy and biological medicine, and particularly provides application of leucine in preparation of a medicine for preventing and / or treating aortic aneurysm. The leucine is independently used or is combined with other medicines for preventing and / or treating aortic aneurysm. The activity of GLUD1 is enhanced through leucine, so that conversion of Glu to alpha-KG is promoted, degradation of Glu is promoted, namely, the Glu level is reduced by enhancing degradation of Glu, and aortic aneurysm is improved. In a Glu metabolic network, Gln can be converted into Glu under the action of glutaminase 1 (GLS1), so that the generation of Glu is inhibited by inhibiting the activity of GLS1, and the effect of preventing and / or treating aortic aneurysm is achieved.

1. Name of the designed product: packing bottle (glutamine powder). 2. Use of the designed product: the designed product is used for packing health-care food. 3. Design points of the designed product: combination of shape and pattern. 4. Picture or photo best indicating the design points: front view.